• Explore /
  • Poster
  • / Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

Abstract Poster

Authors

null

Xavier Leleu

Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France

Xavier Leleu , Maria-Victoria Mateos , Sundar Jagannath , Sosana Delimpasi , Maryana Simonova , Ivan Spicka , Luděk Pour , Iryna Kriachok , Maria Gavriatopoulou , Meletios A. Dimopoulos , Halyna Pylypenko , Holger W. Auner , Benjamin Reuben , Vadim Doronin , Christopher P. Venner , Mamta Garg , Andrew DeCastro , Jatin J. Shah , Sebastian Grosicki , Paul G. Richardson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03110562

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8024)

DOI

10.1200/JCO.2021.39.15_suppl.8024

Abstract #

8024

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Cristina Gasparetto

First Author: Cyrille Touzeau

First Author: Dagmar Hess

First Author: Christopher James Walker